Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Young adult Prader-Willi syndrome growth hormone continuation study
NL-OMON50380Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Oct 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind trial of somatropin in Prader-Willi syndrome (PWS) (2 arms), sponsored by Erasmus MC. Primary endpoints: Optimal growth hormone dosing strategy, Body composition and 5 more. Started Oct 2012; status: completed.
02
Drugs
somatropin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NL-OMON50380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50380.